4.8 Article

Complementary costimulation of human T-cell subpopulations by cluster of differentiation 28 (CD28) and CD81

出版社

NATL ACAD SCIENCES
DOI: 10.1073/pnas.1121307109

关键词

-

资金

  1. National Institutes of Health [CA34233]
  2. Leukemia and Lymphoma Society [LLS 7155]
  3. Albert Yu and Mary Bechmann Foundation

向作者/读者索取更多资源

Cluster of differentiation 81 (CD81) is a widely expressed tetraspanin molecule that physically associates with CD4 and CD8 on the surface of human T cells. Coengagement of CD81 and CD3 results in the activation and proliferation of T cells. CD81 also costimulated mouse T cells that lack CD28, suggesting either a redundant or a different mechanism of action. Here we show that CD81 and CD28 have a preference for different subsets of T cells: Primary human naive T cells are better costimulated by CD81, whereas the memory T-cell subsets and Tregs are better costimulated by CD28. The more efficient activation of naive T cells by CD81 was due to prolonged signal transduction compared with that by CD28. We found that IL-6 played a role in the activation of the nave T-cell subset by CD81. Combined costimulation through both CD28 and CD81 resulted in an additive effect on T-cell activation. Thus, these two costimulatory molecules complement each other both in the strength of signal transduction and in T-cell subset inclusions. Costimulation via CD81 might be useful for expansion of T cells for adoptive immunotherapy to allow the inclusion of naive T cells with their broad repertoire.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Oncology

Serial FNA allows direct sampling of malignant and infiltrating immune cells in patients with B-cell lymphoma receiving immunotherapy

Kelly L. Mooney, Debra K. Czerwinski, Tanaya Shree, Matthew J. Frank, Sarah Haebe, Brock A. Martin, Stefano Testa, Ronald Levy, Steven R. Long

Summary: This study is the largest describing the use of serial FNA sampling to harvest cellular material during immunotherapy clinical trials. The successful use of FNA sampling opens up significant opportunities for future investigations into the dynamic effects of investigational agents, whether they be immunotherapies or targeted therapies.

CANCER CYTOPATHOLOGY (2022)

Article Oncology

Neoadjuvant Intratumoral Immunotherapy with TLR9 Activation and Anti-OX40 Antibody Eradicates Metastatic Cancer

Wan Xing Hong, Idit Sagiv-Barfi, Debra K. Czerwinski, Adrienne Sallets, Ronald Levy

Summary: The combination of synthetic TLR9 ligand CpG and agnostic OX40 antibody can trigger systemic antitumor immune responses, eradicating metastatic disease. Applying this in situ immunotherapy in the neoadjuvant setting can improve survival and minimize adverse effects.

CANCER RESEARCH (2022)

Article Multidisciplinary Sciences

CD81 costimulation skews CAR transduction toward naive T cells

Liora M. Schultz, Debra K. Czerwinski, Ronald Levy, Shoshana Levy

Summary: This study investigates the effect of CD81 costimulation on CAR transduction, finding that it enhances naive T cell activation and results in a CAR T cell product enriched with naive-derived CART cells.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2022)

Article Immunology

Intratumoral immunotherapy relies on B and T cell collaboration

Idit Sagiv-Barfi, Debra K. Czerwinski, Tanaya Shree, Julian J. K. Lohmeyer, Ronald Levy

Summary: Antitumor T cell responses play a crucial role in cancer immunotherapy, but other immune system components are also necessary for effective T cell responses. This study demonstrates that combining Toll-like receptor 9 agonist CpG and Fc-fused IL-12 protein can induce body-wide therapeutic responses in multiple cancer models. These responses depend not only on T cells but also on B cells, which are activated by the treatment and required for optimal T cell activation. The addition of an agonistic antibody against OX40 further enhances T cell activation and therapeutic responses. These findings suggest the potential success of the combination of CpG, anti-OX40, and IL-12Fc in cancer patients and highlight the importance of B and T cell collaboration in this combination immunotherapy.

SCIENCE IMMUNOLOGY (2022)

Article Biochemistry & Molecular Biology

Fingolimod-Conjugated Charge-Altering Releasable Transporters Efficiently and Specifically Deliver mRNA to Lymphocytes In Vivo and In Vitro

Stefano Testa, Ole A. W. Haabeth, Timothy R. Blake, Trevor J. Del Castillo, Debra K. Czerwinski, Ranjani Rajapaksa, Paul A. Wender, Robert M. Waymouth, Ronald Levy

Summary: Charge-altering releasable transporters (CARTs) containing fingolimod were synthesized to enhance mRNA delivery and expression in lymphocytes through ligand-receptor interaction. The fingolimod-conjugated CARTs showed superior transfection of activated T and B lymphocytes in vitro and increased mRNA delivery to specific cell populations in the spleen in vivo.

BIOMACROMOLECULES (2022)

Article Oncology

PARP14 is a novel target in STAT6 mutant follicular lymphoma

Michael Mentz, William Keay, Carolin Dorothea Strobl, Martina Antoniolli, Louisa Adolph, Michael Heide, Axel Lechner, Sarah Haebe, Elisa Osterode, Robert Kridel, Christoph Ziegenhain, Lucas Esteban Wange, Johannes Adrian Hildebrand, Tanaya Shree, Elisabeth Silkenstedt, Annette M. Staiger, German Ott, Heike Horn, Monika Szczepanowski, Julia Richter, Ronald Levy, Andreas Rosenwald, Wolfgang Enard, Ursula Zimber-Strobl, Michael Von Bergwelt-Baildon, Wolfgang Hiddemann, Wolfram Klapper, Marc Schmidt-Supprian, Martina Rudelius, Deepak Bararia, Verena Passerini, Oliver Weigert

Summary: The clinical course of follicular lymphoma (FL) is influenced by the molecular heterogeneity of tumor cells and interactions within the tumor microenvironment (TME). In this study, we found STAT6 mutations in 13% of FL cases, which enhanced the response of FL cells to IL-4 and were associated with increased expression of target genes and nuclear accumulation of pSTAT6. We identified PARP14 as a potential therapeutic target in STAT6-mutated FL cells, as its expression was upregulated and it played a role in the regulatory circuit.

LEUKEMIA (2022)

Meeting Abstract Hematology

Activating Immune Effectors and Dampening Immune Suppressors Generates Successful Therapeutic Cancer Vaccination in Patients with Lymphoma

Tanaya Shree, Sarah Haebe, Debra K. Czerwinski, Erik Eckhert, Grady Day, Anuja Sathe, Susan M. Grimes, Matthew J. Frank, Lauren S. Maeda, Ash A. Alizadeh, Ranjana H. Advani, Richard Hoppe, Steven R. Long, Brock Martin, Michael G. Ozawa, Michael S. Khodadoust, Hanlee P. Ji, Ronald Levy

Meeting Abstract Hematology

Prevalence of Acquired N-Glycosylation Sites at the Single Cell Level in Follicular Lymphoma

Sarah Haebe, Tanaya Shree, Grady Day, Debra K. Czerwinski, Anuja Sathe, Susan M. Grimes, Steven R. Long, Brock Martin, Michael G. Ozawa, Hanlee P. Ji, Ronald Levy

Article Oncology

Rituximab Chimeric Anti-CD20 Monoclonal Antibody Therapy for Relapsed Indolent Lymphoma: Half of Patients Respond to a Four-Dose Treatment Program

Peter McLaughlin, Antonio J. Grillo-Lopez, Brain K. Link, Ronald Levy, Myron S. Czuczman, Michael E. Williams, Meyer R. Heyman, Isabelle Bence-Bruckler, Christine A. White, Fernando Cabanillas, Vinay Jain, Anthony D. Ho, John Lister, Key Wey, David Shen, Brain K. Dallaire

Summary: In this study, the chimeric anti-CD20 antibody IDEC-C2B8 was used to treat patients with relapsed low grade or follicular lymphoma. The response rate was 48%, comparable to single-agent cyto-toxic chemotherapy. Further research is needed to determine the efficacy of this agent and its potential use in combination with standard chemotherapy.

JOURNAL OF CLINICAL ONCOLOGY (2023)

Article Biochemical Research Methods

Lysine-Derived Charge-Altering Releasable Transporters: Targeted Delivery of mRNA and siRNA to the Lungs

Timothy R. Blake, Ole A. W. Haabeth, Adrienne Sallets, Rebecca L. McClellan, Trevor J. Del Castillo, Jose G. Vilches-Moure, Wilson C. Ho, Paul A. Wender, Ronald Levy, Robert M. Waymouth

Summary: Targeted delivery of nucleic acid therapeutics to the lungs shows promise for treating pulmonary diseases. New lysine-derived CART-mRNA complexes (K-CARTs/mRNA) demonstrate selective protein expression in the lungs without additives or targeting ligands. The ability to direct protein expression selectively in the spleen or lungs by simple changes to the CART structure opens new opportunities in research and gene therapy.

BIOCONJUGATE CHEMISTRY (2023)

Article Multidisciplinary Sciences

The molecular mechanism of CD81 antibody inhibition of metastasis

Niroz Abu-Saleh, Chiung-Chi Kuo, Wei Jiang, Ronald Levy, Shoshana Levy

Summary: Metastases are decreased in CD81KO mice. Moreover, a specific anti-CD81 antibody, 5A6, can inhibit metastasis in vivo and invasion and migration in vitro. Removing cholesterol or the intracellular domains of CD81 doesn't affect 5A6's inhibitory effect. The uniqueness of 5A6 is attributed to its recognition of a specific epitope on CD81's large extracellular loop. Finally, several CD81 membrane-associated partners, such as integrins and transferrin receptors, may contribute to the antimetastatic attributes of 5A6.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2023)

Article Biochemistry & Molecular Biology

Single-cell multi-gene identification of somatic mutations and gene rearrangements in cancer

Susan M. Grimes, Heon Seok Kim, Sharmili Roy, Anuja Sathe, Carlos Ayala, Xiangqi Bai, Alison F. Almeda-Notestine, Sarah Haebe, Tanaya Shree, Ronald Levy, Billy T. Lau, Hanlee P. Ji

Summary: In this study, a single-cell method was developed to determine the genotypes of somatic alterations in coding regions of messenger RNAs and integrate these transcript-based variants with their corresponding cell transcriptomes. Nanopore adaptive sampling on single-cell complementary DNA libraries was used to validate coding variants in target gene transcripts, and short-read sequencing was used to characterize the cell types harboring the mutations. CRISPR edits for 16 targets were identified using a cancer cell line, and known variants in the cell line were validated using a 352-gene panel. Variants in primary cancer samples were validated using target gene panels ranging from 161 to 529 genes. A gene rearrangement was also identified in one patient, with the rearrangement occurring in two distinct tumor sites.

NAR CANCER (2023)

Meeting Abstract Oncology

PROFILING THE EFFECTS OF TARGETED TLR9 STIMULATION WITHIN SPONTANEOUSLY ARISING BREAST TUMORS

Caitlyn Miller, Idit Sagiv-Barfi, Patrick Neuhoefer, Debra Czerwinski, Carolyn Bertozzi, Jennifer Cochran, Ronald Levy

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)

Article Biochemistry & Molecular Biology

Systemic delivery of a targeted synthetic immunostimulant transforms the immune landscape for effective tumor regression

Caitlyn L. Miller, Idit Sagiv-Barfi, Patrick Neuhofer, Debra K. Czerwinski, Steven E. Artandi, Carolyn R. Bertozzi, Ronald Levy, Jennifer R. Cochran

Summary: Conjugating an immunostimulant with a tumor-targeted peptide improves the efficacy of systemically administered immunotherapy, transforming the immune-suppressive tumor microenvironment into a lymphocyte-rich environment. Furthermore, this treatment generates tumor-specific CD8(+)T cells.

CELL CHEMICAL BIOLOGY (2022)

Article Oncology

CD20-Targeted Therapy Ablates De Novo Antibody Response to Vaccination but Spares Preestablished Immunity

Tanaya Shree, Vishnu Shankar, Julian J. K. Lohmeyer, Debra K. Czerwinski, Joseph G. Schroers-Martin, Gladys M. Rodriguez, Sara Beygi, Alyssa M. Kanegai, Karen S. Corbelli, Etelka Gabriel, David M. Kurtz, Michael S. Khodadoust, Neel K. Gupta, Lauren S. Maeda, Ranjana H. Advani, Ash A. Alizadeh, Ronald Levy

Summary: In patients with lymphoma, the time since anti-CD20 treatment is an important predictor of neutralizing antibody response to COVID-19 vaccination. Comparing patients who received anti-CD20 treatment before or after vaccination, we demonstrate that vaccinating first can generate a durable antibody response that persists during anti-CD20-containing treatment.

BLOOD CANCER DISCOVERY (2022)

暂无数据